Natco Pharma Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/u64wbxu5u7hzjcv0vw03zox2.pdf

Key Takeaways


Revlimid: The Earnings Reset

Rajeev Nannapaneni: "I think everybody is coming in a staggered way and I think there should be a meaningful amount of money that we are going to make over the next 3-4 years depending on how people enter... the erosion and all it is hard to speculate, I think it will be very premature to talk about how market will form over the new few years."

The COVID Hangover: Write-Offs and Clean-Up

Rajeev Nannapaneni: "I think if you look at the money that we have made over the last few years and look at the write-off, more or less I think on a net basis, it has not really made any money, I think it has been a disaster, but it is what it is, I think business bet that we have made and that has not work."

Base Business: The Treadmill

Rajeev Nannapaneni: "We need to understand how generics business works, I think if you look at the export generic business, everything that we will do will keep reducing every year by 10, 15, 20%... essentially it is a tread mill, so you need to keep coming and launching new products and replacing what you are losing on your base business."

Pipeline and Litigation Bets

Rajeev Nannapaneni: "We look for jackpot opportunities and go after that and there will be uncertainty always, I will not, I never will shy away from saying that, but this is what we do, but when we deliver, we deliver big."

Subsidiaries and Geographic Expansion


Capital Allocation and R&D

Rajeev Nannapaneni: "The thing you need to understand overall generic business and I think if you look at most generic businesses are not growing. It is extremely competitive and the only way you can do something disruptive as you need to buy, otherwise you are not going to get growth and this is the elephant in a room..."

Guidance & Commitments

CommitmentSpecificsTimeline
Revlimid stock liquidation~70% of current Revlimid stock sold, with a good portion in Q1, tapering in Q2/Q3, and bumping up in Q4 with new allocationFY23
Revlimid recurring revenueManagement very confident Revlimid will be recurring and stable; higher share and quantity expected when second-wave generics enterMulti-year, undated
Revlimid remaining strengthsLaunch of remaining two strengths after Reddy's entryUndated, contingent on Reddy's launch
Domestic growth target10–12% growth in the base businessNext year (FY23)
Dash frontend breakevenBreakeven expected with launches from India pipeline1–1.5 years
CTPR clarityClarity on agro inventory and path forward expected; patent expires August 2022, next court hearing July 2022Next 2 months
Upcoming launchAnother big launch in FY23, to be announced shortlyFY23
Agrochemical pipelineVery interesting products to be filedNext 12 months

Key Metrics

MetricQ4 FY22
Consolidated revenue₹610.6 cr, against ₹359.7 cr in Q4 last year
Consolidated net loss₹50.5 cr, against a loss of ₹53 cr in Q4 last year
FY22 consolidated revenue₹2,043.8 cr, against ₹2,155.7 cr last year
FY22 consolidated net profit₹170 cr, against ₹442 cr last year
Inventory write-off (COVID products)₹232 cr for FY22
Provision for estimated credit loss₹46 cr for FY22
Normalized domestic base business (ex-COVID)~₹400 cr
Base business quarterly PAT (ex-Revlimid, incl. subs and India)₹50–60 cr
Revlimid profit shareone third / 30%
Revlimid stock sold in Q4~20–30%; ~70% of stock expected to be sold in FY23
Revlimid Canada market share40–50% (per sales team, IMS not yet out)
Afinitor share of base business sales~30%
Apixaban (generic Eliquis) secondary run rate₹2.5–3 cr per quarter
Agro inventory and supplier commitments at risk₹85 cr
Dash US frontend loss in March quarter₹4–6 cr